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protective capacity.2,9 High levels of Cp were observed to
be an independent risk factor for coronary artery disease
(CAD),10 and our group has further demonstrated that
elevated Cp is an independent predictor of major adverse
cardiovascular events.8 Several recent reports have indi-
cated that Cp levels are elevated in patients with heart fail-
ure (HF), in both acute and chronic states and regardless of
etiology.11,12 Furthermore, serum Cp levels appeared to be
inversely correlated with left ventricular (LV) ejection frac-
tion (LVEF) but directly correlated with symptom severity,
especially in the nonischemic group of patients.11 The
objective of the present study was to examine the prog-
nostic value of Cp in a large well characterized cohort of
patients with a history of HF, particularly in its clinical util-
ity in the context of standard cardiorenal biomarkers such
as B-type natriuretic peptide (BNP).
Methods
Study Population
The Cleveland Clinic Genebank study is a large, prospective
cohort study from 2001 to 2006 comprising stable 9,880 subjects
undergoing elective diagnostic cardiac catheterization procedure.
Each of the research subjects, $18 years old, gave written
informed consent that was approved by the Cleveland Clinic Insti
tutional Review Board. 1,909 patients had a history of HF detected
by 3 methods: a) directly asking patient by research personnel
regarding past medical problems, including self reporting history
of HF; b) reviewing medical records for conﬁrmation, especially
outpatient visits to cardiology department (all patients were seen
by cardiologist at Cleveland Clinic before the left heart catheteri
zation; and c) International Classiﬁcation of Diseases codes and
adjudication by research personnel. This analysis included 890
subjects with a history of HF without evidence of recent acute cor
onary syndrome (cardiac troponin I !0.03 ng/mL) and with
plasma samples available for Cp measurements. An estimate of
creatinine clearance was calculated with the use of the
Cockcroft Gault equation. The presence of clinically relevant
CAD was conﬁrmed by luminal stenosis of $50% in any major
coronary arteries. Adjudicated 5 year all cause survival after
enrollment was ascertained for all subjects by prospective patient
contact as well as chart review and Social Security Death Index
data ascertainment up to 2011.
Sample Storing and Ceruloplasmin Assay
About 70 mL fasting arterial blood was drawn for each patient
on the day of enrollment. Blood was spun and serum samples
placed in small 5 mL tubes. About 7e10 small tubes were stored
at 80C for each patient. Quantitative determination of Cp mass
was performed with the use of an immunoturbidimetric assay (Ar
chitect ci8200; Abbott Laboratories, Abbott Park, Illinois) as pre
viously described.8 All samples had either not previously thawed
or thawed only once before the analysis, which is within the spec
iﬁcations of this FDA approved assay as intended. This assay
provides highly sensitive measurement of Cp levels with an
intra assay coefﬁcient of variation of 3.7%, interassay precision
of up to 4%, and a reference range of 20e60 mg/dL. Serum
BNP levels were measured with the use of an immunoassay on
the same platform.
Statistical Analyses and Patient Grouping
The Student t test or Wilcoxon rank sum test for continuous var
iables and chi square test for categoric variables were used to
examine the difference between assigned groups. We also studied
Cp in combination with BNP. In this combination model, receiver
operator characteristic (ROC) curve analyses and 5 fold cross
validation were used to determine the optimal Cp cutoffs. For a
given cutoff, we used a Cox model to estimate the risk of 5 year
mortality. The 5 fold cross validation divides the data into 5
approximately equal size portions. A Cox model is trained on 4
parts of the data and then estimates the risk of 5 year mortality
in the 5th part. This is repeated for each of the 5 parts. We calcu
lated the area under the ROC curve (AUC) with the estimated risk.
The optimal cutoff is chosen to maximize AUC values. Patients
were grouped based on BNP levels into those with low BNP
(!100 pg/mL), borderline ‘‘gray zone’’ BNP (100e400 pg/mL),
and high BNP (O400 pg/mL), which had previously been re
ported to be associated with increased risk of mortality in HF pa
tients.13 Kaplan Meier analysis and Cox proportional hazards
regression were used for time to event analysis to determine haz
ard ratios (HRs) and 95% conﬁdence intervals (CIs) for 5 year sur
vival. Levels of Cp were then adjusted for traditional coronary
heart disease risk factors in a multivariable model, including
age, sex, systolic blood pressure, body mass index (BMI), low
density lipoprotein cholesterol, high density lipoprotein choles
terol, smoking, diabetics mellitus, creatinine clearance, dialysis
use, and medications (angiotensin converting enzyme [ACE] in
hibitors, beta blockers, statins, nitrate, and aspirin). Analyses
were repeated after adjusting for history of myocardial infarction
(MI), logarithm transformed BNP, LVEF, electrocardiographic
data (heart rate, QRS duration, and left bundle branch block
[LBBB]), and presence of implantable cardioverter deﬁbrillator
(ICD). Net reclassiﬁcation index for evaluating the improvement
in prediction performance gained by adding Cp to all of the afore
mentioned risk factors was calculated according to the Pencina
method.14 All statistical analyses were performed with the use
of SAS version 9.2 (SAS Institute, Cary, North Carolina) and R
2.15.1 (Vienna, Austria).
Results
Study Population
Baseline characteristics of the study population are
shown in Table 1. The mean and median serum Cp levels
were 26.6 mg/dL and 25.6 mg/dL, respectively (interquar-
tile range [IQR] 21.5 30.2 mg/dL). Patients with elevated
Cp levels were more likely to be female and with a history
of diabetes mellitus, but they were also less likely to have
history of coronary artery disease or history of MI.
Correlation With Cardiac and Inﬂammatory Indexes
There was no statistically signiﬁcant correlation between
Cp levels and LVEF (r 5 0.05; P 5 .174). Also, there was
no statistically signiﬁcant association between Cp and
extent of underlying CAD (number of vessels affected).
However, there was a weak correlation between Cp and
plasma BNP levels (r 5 0.187; P ! .001).
Association of Serum Ceruloplasmin Levels With
Survival
A total of 261 patients (29%) died by the 5-year follow-up.
The average time to event was 1,535 days. Table 2 illustrates
the Cox proportional Hazard analysis of increased levels of
Cp with 5-year all-cause mortality outcomes. Compared
with patients with the lowest Cp levels (quartile 1), patients
with increased Cp levels had higher risk of 5-year all-cause
mortality (quartile 4 vs quartile 1 unadjusted HR 1.94,
95% CI 1.36 2.77; P! .001; Table 2; Fig. 1). After adjust-
ing for coronary heart disease traditional risk factors, medi-
cations, creatinine clearance, dialysis use, BMI, history of
MI, BNP, and LVEF, higher Cp remained a signiﬁcant pre-
dictor of increased 5-year mortality (adjusted HR 1.71,
95% CI 1.15 2.55; P ! .01). Analysis was also repeated
after adjustment for heart rate, QRS duration, LBBB, and
ICD placement. In this model, Cp remained an independent
predictor of worse 5-year outcome (Table 2). We also
Table 1. Baseline Characteristics
Demographics
Characteristics
Total
(n 5 890)
Q1
(n 5 225)
Q2
(n 5 222)
Q3
(n 5 221)
Q4
(n 5 222) P Value
Range (mg/dL) 12e54.3 !21.5 21.5e25.6 25.6e30.1 O30.1
Age, y, mean (SD) 66.6 (10) 65.7 (10) 67.1 (10) 67.5 (10) 66 (10) .232
Male, n (%) 543 (61) 194 (86) 148 (67) 116 (52) 85 (38) !.001
BMI, kg/m2, mean (SD) 30 (7) 29 (6) 29 (6) 30 (7) 31 (8) .107
Diabetes mellitus, n (%) 269 (30) 40 (18) 61 (28) 74 (33) 94 (43) !.001
Hypertension, n (%) 670 (76) 175 (79) 167 (76) 161 (74) 167 (77) .572
Hyperlipidemia, n (%) 700 (81) 194 (87) 175 (80) 165 (78) 166 (77) .041
CAD, n (%) 684 (77) 190 (85) 165 (74) 167 (76) 162 (75) .022
MI, n (%) 493 (59) 146 (69) 117 (56) 115 (56) 115 (55) .008
CABG, n (%) 384 (43) 122 (54) 91 (41) 90 (41) 81 (36) .001
Cigarette smoking, n (%) 620 (70) 163 (72) 157 (71) 155 (70) 145 (65) .381
Baseline medications, n (%)
ACE inhibitor 601 (68) 167 (74) 154 (69) 144 (65) 136 (61) .024
Beta blocker 592 (67) 168 (75) 137 (62) 151 (68) 136 (61) .007
Statin 534 (60) 152 (68) 140 (63) 123 (56) 119 (54) .008
Aspirin 566 (64) 154 (68) 142 (64) 135 (61) 135 (61) .303
Nitrate 347 (39) 97 (43) 83 (37) 90 (41) 77 (35) .278
BNP, pg/mL, median (IQR) 300 (114e678) 233 (87e497) 255 (102e563) 371 (162e880) 381 (151e930) !.001
LVEF, %, median (IQR) 35 (25e50) 40 (30e50) 35 (25e50) 35 (25e55) 38 (25e50) .904
Creatinine clearance,
mL min 1
1.73 m 2, median (IQR)
83 (60e110) 88.1 (69.4 117.2) 81.7 (57.2 113.1) 78.4 (55.4 98.5) 80 (54.7 111.2) !.001
Dialysis use, n (%) 19 (2) 8 (4) 6 (3) 3 (1) 2 (1) .013
Electrocardiography data
Heart rate, beats/min,
median (IQR)
71 (62e83) 69 (57e81) 72 (63e82) 71 (63e81) 75 (66e86) !.001
QRS duration, ms,
median (IQR)
108 (94e138) 108 (96e135) 108 (94e138) 108 (94e142) 106 (92e142) .908
LBBB, n (%) 101 (12) 23 (10) 29 (13) 25 (12) 24 (11) .794
Q, quartile; BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; CABG, coronary artery bypass graft surgery; ACE,
angiotensin converting enzyme; BNP, B type natriuretic peptide; IQR, interquartile range; LBBB, left bundle branch block.
Table 2. Hazard Ratio for 5 Year Mortality by Ceruloplasmin (Cp) Quartiles (Qs)
Serum Ceruloplasmin Level (Range)
Q1 Q2 Q3 Q4
Range (mg/dL) !21.5 21.5e25.6 25.6e30.2 $30.2
Unadjusted HR 1 1.34 (0.92e1.95) 1.71 (1.18e2.46)** 1.94 (1.36e2.77)***
Adjusted HR, model 1 1 1.19 (0.81e1.74) 1.64 (1.12e2.41)* 1.93 (1.31e2.85)***
Adjusted HR, model 2 1 1.22 (0.83e1.78) 1.62 (1.11e2.37)* 1.9 (1.29e2.81)***
Adjusted HR, model 3 1 1.3 (0.87e1.94) 1.55 (1.04e2.3)* 1.71 (1.15e2.55)**
Adjusted HR, model 4 1 1.36 (0.91e2.05) 1.57 (1.04e2.37)* 1.68 (1.11e2.53)*
Adjuster HR, model 5 1 1.34 (0.88e2.03) 1.45 (0.95e2.22) 1.68 (1.1e2.55)*
Event rate 47/221 61/223 72/223 81/223
Model 1: Adjusted for coronary heart disease traditional risk factors: age, sex, systolic blood pressure, diabetes, high density lipoprotein, low density
lipoprotein, body mass index, smoking, creatinine clearanc,e and dialysis use; model 2: model 1 plus medications (angiotensin converting enzyme inhibitors,
beta blockers, statins, nitrate, and aspirin); model 3: model 2 plus myocardial infarction, log transformed B type natriuretic peptide and left ventricular ejec
tion fraction; model 4: model 3 plus ventricular rate, QRS duration, and left bundle branch block; model 5: model 4 plus implantable cardioverter deﬁbrillator
placement.
*P ! .05; **P ! .01; ***P ! .001.
stratiﬁed the analysis by history of MI (n5 493). In both MI
and non-MI patients, Cp was associated with increased 5-
year mortality: Q4 vs Q1 HR 1.95 (95% CI 1.03 3.7;
P 5 .041) for the non-MI group and HR 1.98 (95% CI
1.3 3.1; P 5 .003) for the MI group.
We further explored the prognostic value of Cp within
speciﬁc BNP ranges. As illustrated in Figure 2, higher
Cp levels were associated with poorer outcomes compared
with lower Cp levels within each clinically deﬁned BNP
range. The optimal cutoff was 21.5 mg/dL based on
ROC curve analysis. Higher Cp levels showing increased
risk of 5-year mortality within the borderline BNP range
(unadjusted HR 3.2, 95% CI 1.40 7.5; P 5 .006) as
well as in the high BNP range (unadjusted HR 5.8, 95%
CI 2.6 13.1; P ! .001). After adjusting for the afore-
mentioned risk factors, higher Cp still showed increased
mortality risk when within the borderline BNP range
(adjusted HR 3, 95% CI 1.1 8.5; P 5 .036) or the high
BNP range (adjusted HR 4.3, 95% CI 1.5 11.9;
P 5 .006; Fig. 2).
Association Between Ceruloplasmin Levels and Liver
Congestion
Most of our patients had normal levels of liver enzymes:
median (IQR) alanine transaminase (ALT) of 20 (16 26)
U/mL and aspartate transaminase (AST) of 18 (16 26)
U/mL. Slight positive correlation was found between Cp
and ALT (R2 5 0.004; P 5 .048). However, no signiﬁcant
correlation was found between Cp and AST (R2 5 0.003;
P 5 .188). Deﬁning hepatic congestion as having 2 upper
normal range of liver enzymes (AST reference range of
7 40 U/L; ALT reference range 0 45 U/L), only 8 patients
had hepatic congestion. Levels of Cp were not signiﬁcantly
different between groups (medians of 25.9 mg/dL for hepat-
ic congestion group vs 25.6 mg/dL for noncongestion
group; P 5 .99). Cp is a synthetic function of the liver
that would be expected to be low in the setting of liver
congestion, suggesting that our observation is independent
from liver involvement with heart failure.
Discrimination Testing
Both net reclassiﬁcation improvement (NRI) and inte-
grated discrimination improvement were used to quantify
improvement in model performance. P values compare
models with and without Cp. Both models were adjusted
for traditional coronary heart disease risk factors, including
age, sex, systolic blood pressure, diabetes, high-density li-
poprotein, low-density lipoprotein, BMI, smoking, creati-
nine clearance, dialysis use, MI, log-transformed BNP,
LVEF, heart rate, QRS duration, LBBB, and ICD place-
ment. Cutoff values for NRI estimation used a ratio of
6:2:2 for low, medium, and high risk categories. The risk
of mortality was estimated with the use of the Cox model.
The net reclassiﬁcation improvement of Cp for 5-year mor-
tality was 9.33% (P ! .001). The relative integrated
discrimination improvement for this model was 18%
(P ! .001). This is responsible for correctly reclassifying
6.52% and 2.81% of events and nonevents, respectively
(Table 3). The c-statistic of the model also improved
from 0.687 to 0.701 with the addition of Cp but did not
reach statistical signiﬁcance (P 5 .18).
Fig. 1. Kaplan Meier analysis of 5 year survival stratiﬁed accord
ing to ceruloplasmin quartiles.
Fig. 2. Kaplan Meier analysis of 5 year survival in patients with
heart failure based on ceruloplasmin (Cp) and B type natriuretic
peptide (BNP) levels. Using Cp measurements in patients with
different BNP levels (low, !100 pg/mL; borderline, 100e400
pg/mL; or high, O400 pg/mL) can help in identifying
heightened risk HF patients.
Table 3. Reclassiﬁcation With the Use of Ceruloplasmin
(Cp) Levels
Whole Cohort
(n 5 890)
Events correctly reclassiﬁed 6.52%
Nonevents correctly reclassiﬁed 2.81%
Net reclassiﬁcation index 9.33%
Integrated discrimination improvement 18%
Baseline model included age, sex, systolic blood pressure, diabetes,
high density lipoprotein, low density lipoprotein, body mass index, smok
ing, creatinine clearance, dialysis use, myocardial infarction, log
transformed B type natriuretic peptide, left ventricular ejection fraction,
resting heart rate, QRS duration, left bundle branch block, and implantable
cardioverter deﬁbrillator placement.
to form Cp, resulting in low levels of serum Cp.22 Cp levels
do not seem to be related to amount of copper deposition in
the liver or other tissues, given the fact that many Wilson
patients who responded to medical treatment had persis-
tently low levels of Cp levels. Furthermore, patients with
aceruloplasminemia tend to have higher iron deposition in
tissue rather than copper.23,24
The underlying mechanisms for increased Cp expression
in HF are not well understood, but the lack of tight associ-
ation with standard cardiac indexes may suggest an under-
lying metabolic defect at play. Over the past decades, Cp
has been shown to have multiple roles in copper transporta-
tion, coagulation, angiogenesis, defense against oxidant
stress, and iron homeostasis.2,25 In addition to transporting
copper, Cp exhibits a copper-dependent ferroxidase activ-
ity, which is associated with possible oxidation of Fe2þ
(ferrous iron) into Fe3þ (ferric iron), playing a possible
fundamental mechanism of protection from iron-mediated
free radical injury,4,26 inhibiting lipid oxidation,27,28 and
blocking protein and DNA damage.2,25,29 32 Despite these
promising effects, most of these protective enzymatic activ-
ities have been demonstrated only in vitro, warranting
further demonstration in humans particularly in disease
states such as HF. It is important to point out that although
measurement is widely available and inexpensive, clinically
available assays, including the one used in the present
study, represents only the concentration of Cp in the circu-
lation rather than its activity. Interestingly, diminished Cp
ferroxidase activities were observed in substantia nigra tis-
sues of Parkinson disease patients versus control subjects,33
as well as in blood samples of preeclampsia patients versus
control subjects,34 despite similar or increased Cp concen-
trations. This was also seen in a small HF group (n 5 96),
where patients with low Cp ferroxidase activities were
found to have worse disease severity and outcomes.26,35
Thus, there remains an intriguing possibility that the quality
rather than the quantity of Cp may exert a stronger inﬂu-
ence in the function of Cp, and the imbalance of pro- and
antioxidant Cp enzymatic activities may be linked to
heightened rather than diminished downstream nitrative
stress.
In more advanced stages, HF promotes impaired tissue
perfusion. It has been well established that the Cp gene
exhibits multiple hypoxia-responsive elements, and up-
regulation of Cp gene transcription was noticed during hyp-
oxia.36,37 Activation of Cp expression is mechanistically
linked to hypoxia-inducible factor, whereby hypoxia-
response element dependent gene regulation leads to tran-
scriptional induction of the Cp gene promoter.37,38
Recently, Cp has also been shown to have nitric oxide
(NO) oxidase activity in vivo, converting NO, a potent
short-lived vasodilator and antioxidant, to the less active
reservoir form, nitrite.39 It is possible that increased levels
of Cp can decrease available plasma NO, thus enhancing
reactive oxidant species formation and oxidative cell
injury.4,5,39 Interestingly, nitrite can be reduced back to
Discussion
Considering? that? it? is? one? of? the?most? abundant? circu-
lating? glycoproteins? with? a? widely? available? biochemical
measurement? of? its? concentration,? clinicians? have? associ-
ated? low? (rather? than? high)? levels? of? Cp? with? Wilson
disease a? rare? recessive? autosomal? hepatolenticular
degeneration? disease? leading? to? pathologic? deposition? of
copper? in? the? liver,? nervous? system,? and? kidneys.? At? the
other? end? of? the? spectrum,? Cp? is? often? considered? as? an
acute-phase?reactant?that?is?elevated?in?the?settings?of?acute
inﬂammatory? conditions? and? pregnancy1? and? has? been?
widely?measured?in?clinical?practice.?Our?group?and?others
have?previously?observed?that?Cp?has?been?reported?to?be?an
independent?risk?factor?for?CAD,8,10,15 17?and?higher?levels
of? Cp? are? associated? with? adverse? outcomes.8? However,?
despite?early? reports?of?elevated?Cp? levels?and? its?catalytic
activities? in? the? setting? of? acute?MI? in? the? 1950s,18? there?
have? been? limited? investigations? regarding? the? potential
contribution? of? this? relatively? abundant? circulating? glyco-
protein? in? the?development?and?progression?of?myocardial
dysfunction? in? humans.? There? are? several? key? ﬁndings
from?our?study.?For?the?ﬁrst?time,?particularly?in?a?contem-
porary?patient?cohort,?we?observed? that?Cp?provides?prog-
nostic? value? of? 5-year?mortality? in? patients?with?HF? that
was? independent? from? traditional? coronary? heart? disease
risk?factors,?and? the?availability?of?Cp? levels?can?reclassify
risk? for? 5-year? mortality? by? 9.33%.? Second,? the? lack? of
strong? relationship? between? Cp? and? measures? of? HF
severity?such?as?LVEF?and?BNP? implies? that?Cp?may?pro-
vide? distinct? information? of? underlying? pathophysiology.
Taken? together,? the? measurement? of? Cp? (in? combination
with? BNP)? may? help? to? identify? patients? at? heightened
long-term? mortality? risk.? These? ﬁndings,? together? with
earlier? reports?suggesting? the?association?between?elevated
Cp? and? increased? likelihood? of? developing? HF,19? imply?
that?the?mechanistic?underpinnings?of?the?pathophysiologic
role? of? Cp? in? myocardial? dysfunction? warrant? further
investigations.
The?connection?between?Cp?expression?and?development
of?HF?in?humans?is?based?primarily?on?epidemiologic?data.
Data? from? the?Atherosclerosis?Risk? in?Communities? study
also?conﬁrmed? the?ability?of?Cp? to?predict? future?develop-
ment of HF.19?Only?a?few?studies?regarding?association?be-
tween?Cp?and?HF?have?been?done.?Another?study?also?found
increased? incidence?of?HF? in?patients?with?high?Cp? levels
over?22?years?of? follow-up.20?Meanwhile,? in?patients?who?
were? admitted? with? ST-segment elevated? MI,? increased
Cp?levels?were?shown?to?be?associated?with?increased?inci-
dence?of?acute?HF?and?decreased?LVEF.21
Mechanism?of?cardiac? involvement? in?Wilson?disease? is
still?not?very?well?understood;?however,?copper?deposition
is? the? likely?mechanism? causing?myocardial? inﬂammation
and? interstitial?ﬁbrosis.? Interestingly,?defect? in?Wilson?dis-
ease? is? related? to? impairment? in? hepatic? copper? transport
protein,?which?impairs?copper?binding?to?apoceruloplasmin
NO mainly during hypoxic situations.40 Cp-knockout ani-
mals have lower nitrite reservoir, and they were found to
have more hepatocellular infarction after ischemia and re-
perfusion than wild-type animals. Nitrate supplementation
seems to reduce the injury.4 Therefore, increased HF mor-
tality with increased Cp levels could be related to decreased
NO availability in the plasma, or a result of relative tissue
hypoxia given the close gene location to hypoxia-
response element.
Study Limitations
Despite being the largest HF cohort reported with Cp
levels and long-term outcomes, our study population repre-
sents a selected group of patients undergoing elective coro-
nary angiography (w77% of our population has underlying
CAD) with a relatively high proportion of patients with
ischemic HF etiology. Despite ﬁnding signiﬁcant associa-
tion between Cp levels and all-cause mortality, we did
not have complete data about cause of death, hospitaliza-
tion, or consistent echocardiographic indices (such as LV
hypertrophy or diastolic indices). We also did not have
direct measures of Cp function (such as ferroxidase or
NO oxidase activities). Despite these limitations, our
intriguing ﬁndings should prompt further investigations
into how Cp contributes to the pathophysiology of heart
failure.
Conclusion
Ceruloplasmin is an independent predictor of long-term
all-cause mortality in patients with HF. Use of Cp in com-
bination with BNP may help to identify patients at height-
ened mortality risk.
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